Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

By Carola H. Ries, M. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, Flora Rey-Giraud, Leon P. Pradel, F. Feuerhake, I. Klaman and 17 more. Cancer Cell, 2014

1,274 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/49f9e4955015440375191ef57ad9baa885ff8eb2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. Lisa M. Coussens
3. P. Allavena
4. J. Pollard
5. J. Joyce
6. B. Ruffell
7. R. Noy
8. D. Quail

Citations in the corpus

• Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy (2017, background): “The individual CSF1R inhibitors and their different drug-targeting properties have recently been reviewed [13].”
• Macrophage Polarization. (2017, neutral): “Two approaches have been developed to block the CSF-1R: neutralizing monoclonal antibodies to the extracellular region of the receptor (97) and small molecule kinase inhibitors developed by Novartis and Plexxikon.”
• PDL1 Regulation by p53 via miR-34 (2015, result): “Our findings on macrophages and Tregs agree with those of previous studies showing that miR-34a regulates CSF1R, the receptor for CSF1 expressed by macrophages (55,56).”
• Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets (2019, background): “Colony Stimulating Factor 1 (CSF1) is the major macrophage growth factor regulating their survival, differentiation and proliferation and its receptor is therefore a promising target for TAM depletion in cancer (Ries et al., 2014).”
• Tumor-associated macrophages: from mechanisms to therapy (2014, background): “L-arginine is necessary for T cells function, and its depletion inhibits the re-expression of the CD3 z chain after internalization caused by antigen stimulation and TCR signaling (Rodriguez et al., 2003, 2004).”
• The tumor microenvironment underlies acquired resistance to CSF1R inhibition in gliomas (2016, methodology): “In clinical trials, several approaches to inhibit CSF-1R are currently being used, including antibodies and small molecules (7, 11, 12).”